OCCL standalone PAT jumps 220% YoY to ₹27.9 Cr on China supply curbs, margin gains
PAT +220.48% YoY · revenue +114.84% · margins expanding
₹257.04 Cr
+114.84% YoY
₹27.86 Cr
+220.48% YoY
10.82%
+3.6pp YoY
₹5.58
OCCL's standalone (its only basis — no subsidiaries or JVs exist to consolidate) Q2 FY27 PAT rose 220% year-on-year to ₹27.86 Cr on revenue from operations of ₹257.04 Cr, up 115% YoY, with PBT up 226% to ₹37.69 Cr. EPS came in at ₹5.58 against ₹1.74 a year ago. There is no verified Street consensus or brokerage estimate for this specific quarter in the public domain, so vs-street cannot be graded; the company and our records also carry no formal prior guidance, so the print cannot be checked against a management-issued number either — management's commentary is the only outlook on record.
Q2 FY-2027 vs prior quarters
Profitability improved on both lines: EBITDA margin expanded 192 bps YoY to 18.81% (Q2 FY26: 16.89%) and net margin expanded 357 bps to 10.84% (7.27%), as higher Insoluble Sulphur sales volumes and realisations offset elevated raw-material costs through pass-through pricing. Sequentially, PAT fell 30.8% from Q1 FY27's ₹40.25 Cr and EBITDA margin was down from the high-20s — but this is not a Q2 weakness: management explicitly attributes Q1's stronger showing to an inventory valuation gain, a one-off that inflated the prior quarter rather than Q2 falling short. Judged YoY, which is the primary read, the quarter was broadly strong.
The stock went into the print at ₹166.5, down 23.3% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; revenue is at a 6-quarter high.
The demand backdrop ties directly to this quarter's regulatory developments: domestic demand was aided by provisional anti-absorption duties curbing Chinese imports and precautionary inventory stocking amid geopolitical uncertainty, while global demand firmed on Chinese supply constraints — limited sulphur availability, shipping disruptions, and the Huatai plant closure. Two post-quarter developments extend this tailwind: an anti-dumping duty increase on Chinese insoluble sulphur imports effective September 30, 2026, and a CVD investigation into Chinese imports initiated October 8, 2026. The board declared an interim dividend of ₹2/share (record date November 13, 2026) for FY27. Management (CMD Arvind Goenka) framed the balance sheet as "lean... with low debt and strong cash flows" — but that sits awkwardly against the actual cash statement: H1 FY27 operating cash flow was negative ₹40.68 Cr (H1 FY26: +₹12.64 Cr) as inventories rose ₹72.86 Cr and receivables ₹68.48 Cr on the higher raw-material cost base, funded by current borrowings nearly doubling to ₹156.68 Cr from ₹78.64 Cr. The earnings growth is real, but it has not yet converted to operating cash this half.
W1
Whether the 18.81% EBITDA margin holds next quarter without a Q1-style inventory gain, given management's stated focus on "timely pass-through of raw material cost increases, protecting per M.T. contribution margins"
W2
Working-capital trajectory: H1 operating cash outflow of ₹40.68 Cr against current borrowings now at ₹156.68 Cr, as management flags "higher sales prices and working capital requirements" from raw-material cost increases
W3
Outcome of the CVD investigation into Chinese insoluble sulphur imports (initiated Oct 8, 2026) and the anti-dumping duty increase effective Sep 30, 2026 — both flagged by the company as current demand drivers
Standalone only — company has no subsidiaries/JVs/associates requiring consolidation under Ind AS-28 (filing note 3), so no consolidated statement exists. All figures converted from ₹ Lakhs. No exceptional items in Q2 FY27 or the Q2 FY26 comparator (FY26's ₹2.06 Cr Labour Codes exceptional item sits only in the full-year column); arithmetic ties out exactly (revenueFromOps+otherIncome=totalIncome; PBT−tax=PAT).